Publications by authors named "P Barton Duell"
Adverse cardiovascular (CV) events have declined in Western countries due at least in part to aggressive risk factor control, including dyslipidemia management. The American and European (Western) dyslipidemia treatment guidelines have contributed significantly to the reduction in atherosclerotic cardiovascular disease (ASCVD) incidence in the respective populations. However, their direct extrapolation to Indian patients does not seem appropriate for the reasons described below.
View Article and Find Full Text PDFArticle Synopsis
- Despite the availability of lipoprotein-lowering medications, some high-risk patients with persistent high cholesterol may need alternative treatments like lipoprotein apheresis (LA).
- LA is particularly beneficial for individuals with familial hypercholesterolemia and not only lowers cholesterol but also improves heart function and reduces inflammation.
- While studies show LA leads to better cardiovascular outcomes, its use in the U.S. is limited, and more research is needed on its benefits for certain kidney conditions.
Article Synopsis
- Rapid LDL-C reduction post-acute coronary syndrome (ACS) is crucial for future event prevention, but high-dose statins alone often don't meet LDL-C targets.
- Combining rosuvastatin, ezetimibe, and bempedoic acid (REB) in a study showed significant LDL-C decreases from baseline levels, achieving reductions within just one week.
- The triple therapy allowed over 76% of patients to reach recommended LDL-C levels quickly, making it a viable and affordable option for treatment in India.